Antonio Agostini

Antonio Agostini


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
Marta ChiaravalliMarta Chiaravalli
Marta Chiaravalli
ASAlexia Spring
Alexia Spring
AAAntonio Agostini
Antonio Agostini
GPGeny Piro
Geny Piro
CCCarmine Carbone
Carmine Carbone
Giampaolo TortoraGiampaolo Tortora
Giampaolo Tortora
Immunogenic cell death (ICD) is a regulated form of cell death that induces the activation of both innate and adaptive immune responses through the release of damage-associated molecular patterns (DAMPs) and their subsequent recognition by pattern-recognition receptors (PRRs), generating specific CD8+ T lymphocytes. Thus, ICD inducers (such as certain chemotherapeutic agents, targeted therapies, radiation, and oncolytic viruses) could become a potential cancer treatment by providing antitumour immunity and cancer vaccination. Moreover, their combination with immunotherapy, especially with immune checkpoint inhibitors, could overcome the immunosuppressive tumour microenvironment that characterises certain cancers, including gastrointestinal cancers. This review will provide insights into the role of ICD induction in colorectal, gastric, pancreatic, and hepatocellular carcinomas. Specifically, we will discuss the main mechanisms involved in ICD, their potential application in gastrointestinal cancer treatment, and the latest clinical trial updates.

23 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PMPanebianco Martina
Panebianco Martina
CCChiara Ciccarese
Chiara Ciccarese
ASAlessandro Strusi
Alessandro Strusi
VBViria Beccia
Viria Beccia
CCCarmine Carbone
Carmine Carbone
RIRoberto Iacovelli
Roberto Iacovelli
In recent years, the first-line available therapeutic options for metastatic renal cell carcinoma (mRCC) have radically changed with the introduction into clinical practice of new immune checkpoint inhibitor (ICI)-based combinations. Many efforts are focusing on identifying novel prognostic and predictive markers in this setting. The complement system (CS) plays a central role in promoting the growth and progression of mRCC. In particular, mRCC has been defined as an “aggressive complement tumor”, which encompasses a group of malignancies with poor prognosie and highly expressed complement components. Several preclinical and retrospective studies have demonstrated the negative prognostic role of the complement in mRCC; however, there is little evidence on its possible role as a predictor of the response to ICIs. The purpose of this review is to explore more deeply the physio-pathological role of the complement in the development of RCC and its possible future use in clinical practice as a prognostic and predictive factor.